VCEL Q2 2024 Earnings — Vericel Corporation Revenue & Financial Results | Market Cap Arena

VCELVericel Corporation

$2B

Q2 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$53M+14.7% YoY

Gross Profit

$37M69.5% margin

Operating Income

-$6M-11.5% margin

Net Income

-$5M-8.9% margin

EPS (Diluted)

$-0.10

QoQ Revenue Growth

+2.7%

Cash Flow

Operating Cash Flow

$19M

Free Cash Flow

$2M

Stock-Based Comp.

$10M

Balance Sheet

Total Assets

$377M

Total Liabilities

$134M

Stockholders' Equity

$243M

Cash & Equivalents

$50M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$53M	$46M	+14.7%
Gross Profit	$37M	$30M	+22.2%
Operating Income	-$6M	-$6M	-1.2%
Net Income	-$5M	-$5M	+6.7%

Revenue Segments

MACI Implants And Kits

$44M100%